Century Therapeutics 2025 net loss narrows beating estimates

Reuters03-12 20:10
Century <a href="https://laohu8.com/S/LENZ">Therapeutics</a> 2025 net loss narrows beating estimates

Overview

  • US biotechnology firm's 2025 net loss narrowed, beating analyst expectations

  • Collaboration revenue for 2025 surged, driven by Bristol-Myers Squibb agreement

  • Company completed $135 mln private placement, extending cash runway into Q1 2029

Outlook

  • Century expects to submit CNTY-813 IND in 4Q 2026, with initial clinical data in 2H 2027

  • Company expects CNTY-308 to enter the clinic in 2026, pending regulatory clearance

  • Century anticipates updated preliminary clinical data from the CARAMEL study in 2026

Result Drivers

  • COLLABORATION REVENUE - Surge in collaboration revenue attributed to Bristol-Myers Squibb agreement

  • LOWER R&D AND G&A COSTS - Decline in research and development and administrative expenses due to reduced personnel, manufacturing, and legal costs

Company press release: ID:nGNX7Qd8DN

Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

FY Collaboration Revenue

$109.16 mln

FY Net Income

Beat

-$9.58 mln

-$14.72 mln (3 Analysts)

FY Operating Income

Beat

-$17.27 mln

-$20.86 mln (3 Analysts)

FY Basic EPS

-$0.14

FY Operating Expenses

$126.43 mln

Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the biotechnology & medical research peer group is "buy"

  • Wall Street's median 12-month price target for Century Therapeutics Inc is $4.00, about 46.5% above its March 11 closing price of $2.73

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment